MAP Pharmaceuticals
Allergan in $958m neurology deal
January 25, 2013Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine
Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
